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What is Massively Parallel Sequencing? What anomalies can be 
detected? 
What are the advantages and limitations? 
What can be expected in the future? 
Conclusions 
Introduction 
The risk of miscarriage of invasive prenatal tests, like amniocentesis or chorionic villus sampling, has led to the development of non-invasive prenatal tests. These tests 
are only screening tests but they assess the risk of carrying a fetus with an anomaly, reducing the number of invasive tests that have to be performed. In 1997, the 
presence of fetal cell-free DNA (cfDNA) in maternal plasma during pregnancy was demonstrated (aprox. 10% of total cfDNA in maternal plasma) and, since then, a 
variety of methods have been used to analyse it as a prenatal test. The most used method nowadays is Massively Parallel Sequencing (MPS). 
 
OBJECTIVE: to do a bibliographic research to describe the MPS technique and its applications in prenatal diagnosis, the kind of anomalies that can be detected, the 
advantages and limitations of this method and the future expectations.  
MPS:  
DNA sequencing technique that allows a large-scale 
production of genomic sequences (reads) rapidly and 
simultaneously in a single run.  
 
MPS used for the study of cfDNA in maternal 
plasma:  
The approach is based in comparing the number of 
reads mapping to a chromosome of interest with the 
number of reads mapping to normal chromosomes of 
reference (known as counting). There is the need to 
determine a threshold to stablish the quantity of 
reads at which one chromosome is considered over- 
or under-represented. 
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ADVANTAGES 
There is no need to differentiate between the fetal and the maternal DNA 
Can detect all the common aneuploidies in just one test 
Can be performed with small fractions of fetal cfDNA in maternal plasma 
Can be done after 10 weeks of gestation (1r trimester) 
Applicable in all pregnancies and independent of the gender of the fetus 
Has a high sensitivity (true positive rate ≥90%) and specificity (true  
negative rate ≥99%) 
Has a very low false positive rate (1-3%) and false negative  
rate (<1%) → however, they have to be considered in every case 
LIMITATIONS 
High cost and time consuming technique 
There is a bias due to the GC content of every chromosome (chromosomes  
are amplified faster or more slowly depending on the GC content) → can be 
corrected using bioinformatics algorithms 
Cannot detect polyploidies or single gene disorders (qualitative anomalies) 
Difficulties to detect mosaicism cases (placental, fetal or maternal mosaicisms) 
Some difficulties with multiple pregnancies 
This techniques is only a SCREENING TEST → positive results have to be  
confirmed by invasive procedures 
Targeted sequencing 
Sequencing only the chromosomes of 
interest. 
 Lower cost 
Only detects anomalies in the 
chromosomes studied and has 
lower sensitivity and specificity 
Subchromosomal abnormalities  
Detection of abnormalities that only 
affect a part of the chromosome. 
 Detection at a higher resolution 
than traditional karyotyping 
Requires high fractions of fetal 
cfDNA 
Molecular karyotype 
Determination of the ploidy of every 
chromosomic region. 
 Study of deletions or duplications 
among all the genome 
Requires a higher throughput 
increasing the cost 
Whole-genome sequencing 
Sequencing all the fetal genome. 
 Detection of both quantitative and 
qualitative anomalies.  
Requires the genetic maps of the 
mother and the father and has a 
high cost 
MPS is a very effective technique for the analysis of quantitative abnormalities in the fetus. 
It is indicated in pregnant women with an increased risk of carrying a fetus with an 
aneuploidy, but not in average risk mothers. 
Allows a significant reduction in high risk women who will have to undergo invasive tests. 
It implies some ethical concerns among a part of the population. 
Improvements in the technique are expected to turn it into a DIAGNOSTIC TEST. 
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